Literature DB >> 30410993

Elongated EABR wave latencies observed in patients with auditory neuropathy caused by OTOF mutation.

Makoto Hosoya1, Shujiro B Minami1, Chieko Enomoto1, Tatsuo Matsunaga2,3, Kimitaka Kaga1,4.   

Abstract

OBJECTIVES: We sought to determine how the pathology altered electrically evoked auditory brainstem responses (EABRs) in patients with hearing loss by evaluating EABRs in auditory neuropathy patients with OTOF mutations comparing with various types of congenital deafness.
METHODS: We included 15 patients with congenital hearing loss, grouped according to pathology: OTOF mutations (n = 4), GJB2 mutations (n = 4), SLC26A4 mutations (n = 4), or cytomegalovirus infections (n = 3). EABRs were recorded when patients underwent cochlear implantation surgery. We evaluated the latencies and amplitudes of the recorded EABRs and compared them statistically between four groups.
RESULTS: The EABR latencies of Wave III and Wave V, and of the interval between them, were significantly longer in the OTOF mutation group than in the GJB2 and SLC26A4 mutation groups (Wave III) and in all three other groups (Wave V and Wave III-V latency); amplitudes were not significantly different between groups.
CONCLUSIONS: Our results suggest OTOF mutations cause delayed (or slowed) postsynaptic neurotransmission, although the presumed mechanism involved reduced presynaptic transmission between hair cells and spiral ganglion neurons. LEVEL OF EVIDENCE: Mainly a case report.

Entities:  

Keywords:  Auditory neuropathy; OTOF; electrically evoked auditory brainstem responses

Year:  2018        PMID: 30410993      PMCID: PMC6209615          DOI: 10.1002/lio2.210

Source DB:  PubMed          Journal:  Laryngoscope Investig Otolaryngol        ISSN: 2378-8038


INTRODUCTION

Auditory neuropathy (AN) is a disease characterized by absent or abnormal auditory nerve function with normal outer hair cell function. Clinically, AN presents as sensorineural hearing loss with accompanying impaired speech discrimination; diagnostic data are characterized by preserved otoacoustic emissions (OAE) or cochlear microphonic (CM) and a disturbed auditory brain stem response (ABR).1, 2 A part of AN is known to be caused by genetic mutations including OTOF,3 OPA1,4 and PJVK mutations.5 In fact, an OTOF mutation was first reported as a genetic cause of DFNB9.6 OTOF mutations account for 1.4% to 5% of cases of autosomal recessive non‐syndromic hearing impairment.7, 8, 9, 10, 11, 12, 13, 14 The majority of patients carrying two mutant alleles of OTOF show severe‐to‐profound congenital hearing loss. In Japanese patients with AN, OTOF mutations accounted approximately 60% of the cases.15 Within at least the first one or two years after birth they show preserved OAE or CM without an ABR response,16 so they are diagnosed with AN. The trans‐membrane protein OTOFERLIN, encoded by the OTOF gene, is expressed in the inner and outer hair cells of the rodent cochlea.6, 17 This protein is a critical regulator of vesicle fusion with the plasma membrane following glutamate release or during the need for vesicle replenishment at the afferent ribbon synapses between inner hair cells and spiral ganglion neurons.18 Thus, AN caused by OTOF mutation is thought to be caused by disrupted synaptic function (an auditory synaptopathy) at synapses between the inner hair cells and spiral ganglion neuron.19 Treatment of profound‐to‐severe hearing loss in patients with AN requires cochlear implantation (CI); however, the efficacy of CI in such cases is controversial.20, 21, 22, 23, 24 On the other hand, AN caused by OTOF mutations is thought to be a better candidate for cochlear implantation because the electrode can stimulate the auditory nerves directly, thus bypassing impaired synapses. Several reports have demonstrated an adequate level of cochlear implant performance in patients with OTOF mutations.25, 26, 27 However, precise evaluations of postsynaptic functions in this disease are lacking. Electrically evoked auditory brainstem responses (EABRs) can be used for measuring neuronal activity in the cochlear nerve after CI implantation; in addition, the clinical usefulness of EABR analysis has been reported.28, 29 Thus far, electrophysiological investigations were reported using EABR analysis in AN patient.30, 31, 32, 33 Runge et al. showed reduced wave V supra‐threshold amplitude with AN and indicated residual dys‐synchronous neuronal activity in the central auditory pathway.31 Given the heterogeneity of potential cause of AN, grouping the patient by the cause is needed. In this report we focused on AN caused by OTOF mutations. To clarify the postsynaptic neuronal physiological changes in auditory neuropathy caused by OTOF mutations, we compared the EABR responses of patients who underwent CI to treat one of several forms of congenital hearing loss. We also compared the physiological characteristics of EABRs after long‐term or short‐term cochlear implantation for patients with OTOF mutations.

MATERIALS AND METHODS

Enrolled Patients

We retrospectively analyzed the EABR results of patients who had undergone CI from December 2008 to November 2016, with implants manufactured by MED‐EL or Advanced Bionics; we had to exclude implants manufactured by Cochlear for technical reasons. We included patients who were diagnosed with OTOF, GJB2, or SLC26A4 mutations by genetic testing, and who were diagnosed with maternal CMV infections by umbilical cord inspection. We enrolled 15 patients, including four each with OTOF, GJB2, or SLC26A4 mutations; and three patients with previous maternal CMV infections. Among these patients, four patients had undergone bilateral CI. We analyzed EABR wave forms obtained from six ears with OTOF mutations, six with GJB2 mutations, four with SLC26A4 mutations, and four from patients with CMV infections (Table 1).
Table 1

Enrolled Patients, Their Demographic Characteristics, and Their Pathological Findings

PatientCause of DeafnessSexOperation AgeOperation sideImplanted CI modelImaging FindingsWave III Latency (mSec)Wave V Latency (mSec)
#1 OTOF Male3Y4MrtMED‐EL PULSAR FLEX softno inner ear malformation2.244.65
#2 OTOF Female1Y9MrtMED‐EL CONCERTO flex28no inner ear malformation2.665.60
#2‐2nd OTOF Female3Y0MltMED‐EL CONCERTO flex28no inner ear malformation2.705.49
#3 OTOF Female2Y3MrtAdvanced Bionics Hifocus MSno inner ear malformation2.345.28
#3‐2nd OTOF Female2Y10MltAdvanced Bionics Hifocus MSno inner ear malformation2.345.28
#4 OTOF Female1Y11MrtAdvanced Bionics Hifocus MSno inner ear malformation2.444.46
#5 GJB2 Male2Y1MrtMED‐EL PULSAR FLEX softno inner ear malformation2.364.19
#5‐2nd GJB2 Male5Y5MltMED‐EL CONCERTO flex28no inner ear malformation2.004.30
#6 GJB2 Male1Y6MrtMED‐EL CONCERTO MI1000PIN flex softno inner ear malformation2.134.34
#6‐2nd GJB2 Male2Y1MltMED‐EL CONCERTO flex28no inner ear malformation2.204.06
#7 GJB2 Male2Y7MrtMED‐EL CONCERTO flex28no inner ear malformation2.024.39
#8 GJB2 Male3Y6MrtMED‐EL CONCERTO Flex28no inner ear malformation2.224.08
#9 SLC26A4 Male1Y11MrtMED‐EL CONCERTO Mi100 Flex softlarge vestibular aqueduct2.123.97
#10 SLC26A4 Female3Y5MrtMED‐EL CONCERTO Mi100 Flex softlarge vestibular aqueduct2.314.07
#11 SLC26A4 Female4Y0MrtAdvanced Bionics Mid Scalalarge vestibular aqueduct2.204.00
#12 SLC26A4 Female3Y10MrtMED‐EL CONCERTO flex28large vestibular aqueduct2.083.86
#13CMVFemale3Y8MltMED‐EL CONCERTO flex28no inner ear malformation2.384.26
#14CMVMale3Y8MltMED‐EL CONCERTO flex28no inner ear malformation2.064.17
#15CMVFemale1Y6MltMED‐EL CONCERTO flex28no inner ear malformation2.214.15
#15‐2ndCMVFemale2Y1MrtMED‐EL CONCERTO flex28no inner ear malformation2.214.37

Notes: * The note “2nd” in the Patient column represents the second operation undergone by that patient. CI = cochlear implant; CMV = cytomegalovirus.

Enrolled Patients, Their Demographic Characteristics, and Their Pathological Findings Notes: * The note “2nd” in the Patient column represents the second operation undergone by that patient. CI = cochlear implant; CMV = cytomegalovirus. Deafness genes were tested at the Laboratory of Auditory Disorders, National Institute of Sensory Organs, National Tokyo Medical Center by the Sanger method using the genomic DNA extracted from patients' peripheral blood cells when their deafness genes have not been clarified by previous genetic testing performed by BML supported by National Health Insurance. We performed the Sanger methods as previously reported.15, 34, 35 Genes and mutations of the enrolled patients are shown in Supplementary Table 1. While c.3256G>A (p.G1086R) mutation of OTOF gene has not been reported as a pathogenic mutation, according to the ACMG guideline,36 we concluded it as a likely pathogenic mutation because this variant fulfilled PM2, PM3, PP3, and PP4. Similarly, c.1264‐2A>G mutation of SLC26A4 gene also has not been reported as a pathogenic mutation, but we concluded it as a pathogenic mutation because this variant fulfilled PVS1, PM2, PM3, and PP4. All procedures were approved by the Ethics Review Committee of National Hospital Organization Tokyo Medical Center, Japan and other participating institutions, and were conducted only after written informed consent had been obtained from each subject or from the parents of the subjects.

Measurement of EABR

EABRs were recorded as described previously.28 In brief, they were recorded by stimulating each electrode of cochlea implant in the cochlea using the Neuropack Σ (Nihon Koden Co., Tokyo, Japan) electrodiagnostic system, which was triggered externally by the stimulus output of the proprietary MED‐EL or Advanced Bionics software and interface unit. The interface unit was also connected to a stock speech processor, which transmitted the stimulus signal across the skin to the implanted device. The electrically evoked brainstem potentials were recorded by using needle electrodes placed on the forehead (different electrode) and nape (indifferent electrode), and the reference electrode was placed on the contralateral shoulder. The recording of electrical activity included two or three replications of 1000 sweeps at each stimulus level, with a time window of 10 ms for each stimulus condition. Frequency cut‐offs of 100 and 1000 Hz were used. The pulse duration was set to 30 μs and the stimulation amplitude for a single recording fell from 1200 current unit (cu) to 200 cu at 200 cu intervals for MED‐EL and 600 cu to 200 cu at 100 cu intervals for Advanced Bionics. If no response was detected, pulse duration was increased up to 100 μsec.

Categories of Auditory Performance (CAP) Scale

For accessing speech perception, we used CAP scale, which comprises a hierarchical scale of auditory perceptive ability. In this scale, the lowest level (0) describe no awareness of environmental sounds and the level (7) is presented by the ability to use a telephone with a known speaker.37, 38

Statistical Analysis

Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 23.0 (Armonk, New York, USA). For multiple comparisons, we used the Tukey–Kramer method. The results of multiple experiments are presented as the mean ± standard deviation. All tests used a P value of .05 as the threshold for significance.

RESULTS

Representative EABR waveforms obtained from each group, and the aspects of the waveforms that were analyzed, are shown in Figure 1. We compared latencies and amplitudes of Wave III and Wave V in this study. The Wave V latencies were significantly longer in the group with OTOF mutations than in any other group (Fig. 2A); however, no difference was observed in amplitudes (Fig. 2B). When we compared Wave III latencies and amplitudes, the latencies were significantly longer in the OTOF mutation group relative to the GJB2 and SLC26A4 mutation groups, but not the CMV group (Fig. 3A). No significant differences were observed in Wave III amplitudes (Fig. 3B). Amplitudes in all groups were found to have very high standard deviations. We also analyzed the latency difference between Wave III and Wave V across groups. The Wave III–Wave V latencies were also significantly longer in the OTOF group than in all other groups (Fig. 4).
Figure 1

Representative evoked auditory brainstem response wave forms for each group. Groups were composed according to the identified pathology (OTOF, GJB2, or SLC26A4 mutations or cytomegalovirus [CMV] infection).

Figure 2

Comparison of evoked auditory brainstem response (EABR) Wave V latencies (A) and amplitudes (B) between pathology groups.

EABR Wave V latency was significantly longer in patients with OTOF mutations than those in all other groups; no significant changes were observed in Wave V amplitudes between the groups. ** P < .01

Figure 3

Comparison of Wave III latencies (A) and amplitudes (B) between groups.

The evoked auditory brainstem response Wave III latency was significantly longer in patients with OTOF mutations than in those with GJB2 and SLC26A4 mutations, but not in those with CMV infection; no significant changes were observed in wave III amplitudes between the groups. ** P < .01, * P < .05

Figure 4

Comparison of the latencies from Wave III to Wave V between groups.

The latency between evoked auditory brainstem response Wave III and Wave V was significantly longer in patients with OTOF mutations than in all other groups. ** P < .01, * P < .05

Representative evoked auditory brainstem response wave forms for each group. Groups were composed according to the identified pathology (OTOF, GJB2, or SLC26A4 mutations or cytomegalovirus [CMV] infection). Comparison of evoked auditory brainstem response (EABR) Wave V latencies (A) and amplitudes (B) between pathology groups. EABR Wave V latency was significantly longer in patients with OTOF mutations than those in all other groups; no significant changes were observed in Wave V amplitudes between the groups. ** P < .01 Comparison of Wave III latencies (A) and amplitudes (B) between groups. The evoked auditory brainstem response Wave III latency was significantly longer in patients with OTOF mutations than in those with GJB2 and SLC26A4 mutations, but not in those with CMV infection; no significant changes were observed in wave III amplitudes between the groups. ** P < .01, * P < .05 Comparison of the latencies from Wave III to Wave V between groups. The latency between evoked auditory brainstem response Wave III and Wave V was significantly longer in patients with OTOF mutations than in all other groups. ** P < .01, * P < .05 Finally, in order to evaluate the clinical relevant of this elongation of EABR wave form, we compare the patients' speech perception between the groups evaluated by CAP score. There was no significant difference between the groups (Fig. 5A). Moreover, there was no significant relationship between CAP score and EABR latency (Fig. 5B).
Figure 5

Comparison of CAP score between the groups.

There was no significant difference between the groups (A). No significant relationship was detected between CAP score and EABR latency (B).

Comparison of CAP score between the groups. There was no significant difference between the groups (A). No significant relationship was detected between CAP score and EABR latency (B).

DISCUSSION

Our EABR analyses revealed what appears to be delayed postsynaptic neurotransmission in AN caused by OTOF mutations. We also noted that these results indicated that postsynaptic activity was still disturbed after CI implantation. However, OTOF mutations induce presynaptic insufficiency at the synaptic junctions of the hair cells and spiral ganglion neurons. Given these observations, we suggest that cochlear nerve synchronies were reduced in the OTOF group, whereas primarily neuronal conduction was preserved. Nerve development and nervous system maturation resulting in firing synchrony develops through increasing electrical pre‐ and postsynaptic stimulation.39, 40 The disturbed synchronies also observed with OTOF mutations could be caused by insufficient presynaptic stimulation, and/or the delay of nervous system maturation including the pre‐ and postsynaptic neural network. It is also possible that the OTOF mutation disturbs neurotransmission in not only hair cell‐spiral ganglion synapses, but also in the cochlear nucleus or other more central aspects of the auditory pathway. Thus far, OTOF expression in the central auditory pathway includes spiral ganglion neurons has not been reported in the adult rodent. However, its expression was reported in other parts of the central nervous system, including the cerebellum, in the rat.17 Our results suggest that otoferlin is important in normal neurotransmission in the human central auditory pathway, although there are no reports on otoferlin expression in primate or human. A more detailed expression study of the auditory pathway in primates will need to be carried out in near future. Our results showed that the latencies of Wave III and Wave V in patients with AN due to OTOF mutations were longer than those in patients with AN due to other mutations or CMV. Thus far, Runge et al. documented poor post‐synaptic ECAP response in one of two patients with an OTOF mutation.41 Our observation with EABR analysis is compatible with their report. Some reports have mentioned that postoperative speech and hearing ability is affected by the EABR latencies, and that longer latencies (greater delays) might predict poorer outcomes.42, 43 Whereas patients with OTOF mutations generally respond well to CI and actually we could not point out clinical relevant with this elongation of EABR wave form by CAP score (Fig. 5A,B), our result suggest there is a hidden negative effect on neurotransmission between the cochlear implant and the brain which cannot be detected by CAP score. Our results suggest the need for more careful follow‐up of the effects of CI implantation in patients with AN caused by OTOF mutations. Moreover, it is possible that neuronal maturation mediated by CI would be observed. A larger‐scale study with follow‐up analysis will need to be carried out in near future. In conclusion, we unveiled a novel pathophysiology of auditory neuropathies caused by OTOF mutations which affect more central auditory pathway beyond the synapse between the hair cells and spiral ganglion neurons. We also found that EABRs are useful for clarifying the pathophysiology of congenital hearing loss with cochlear implants.
  43 in total

1.  Usefulness of measuring electrically evoked auditory brainstem responses in children with inner ear malformations during cochlear implantation.

Authors:  Shujiro B Minami; Hideki Takegoshi; Yukiko Shinjo; Chieko Enomoto; Kimitaka Kaga
Journal:  Acta Otolaryngol       Date:  2015-06-10       Impact factor: 1.494

2.  Outcome of cochlear implantation in pediatric auditory neuropathy.

Authors:  Emily Buss; Robert F Labadie; Carolyn J Brown; Aimee J Gross; John H Grose; Harold C Pillsbury
Journal:  Otol Neurotol       Date:  2002-05       Impact factor: 2.311

3.  Identifying cochlear implant channels with poor electrode-neuron interfaces: electrically evoked auditory brain stem responses measured with the partial tripolar configuration.

Authors:  Julie Arenberg Bierer; Kathleen F Faulkner; Kelly L Tremblay
Journal:  Ear Hear       Date:  2011 Jul-Aug       Impact factor: 3.570

4.  The Relationship Between EABR and Auditory Performance and Speech Intelligibility Outcomes in Pediatric Cochlear Implant Recipients.

Authors:  Yu Wang; Tao Pan; Shruti Balvalli Deshpande; Furong Ma
Journal:  Am J Audiol       Date:  2015-06       Impact factor: 1.493

5.  Identification of a novel splice site variant of OTOF in the Korean nonsyndromic hearing loss population with low prevalence of the OTOF mutations.

Authors:  Young Ju Jin; Jaehong Park; Ah Reum Kim; Yoon Chan Rah; Byung Yoon Choi
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2014-04-24       Impact factor: 1.675

6.  Screening of OTOF mutations in Iran: a novel mutation and review.

Authors:  Nejat Mahdieh; Atefeh Shirkavand; Bahareh Rabbani; Mustafa Tekin; Bahman Akbari; Mohammad Taghi Akbari; Sirous Zeinali
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2012-08-18       Impact factor: 1.675

7.  Subgroups of enlarged vestibular aqueduct in relation to SLC26A4 mutations and hearing loss.

Authors:  Yasuhide Okamoto; Hideki Mutai; Atsuko Nakano; Yukiko Arimoto; Tomoko Sugiuchi; Sawako Masuda; Noriko Morimoto; Hirokazu Sakamoto; Noboru Ogahara; Akira Takagi; Hidenobu Taiji; Kimitaka Kaga; Kaoru Ogawa; Tatsuo Matsunaga
Journal:  Laryngoscope       Date:  2013-12-17       Impact factor: 3.325

8.  Categories of auditory performance: inter-user reliability.

Authors:  S Archbold; M E Lutman; T Nikolopoulos
Journal:  Br J Audiol       Date:  1998-02

9.  Novel OTOF mutations in Brazilian patients with auditory neuropathy.

Authors:  Jihane Romanos; Lilian Kimura; Mariana Lopes Fávero; Fernanda Attanasio R Izarra; Maria Teresa Balester de Mello Auricchio; Ana Carla Batissoco; Karina Lezirovitz; Ronaldo Serafim Abreu-Silva; Regina Célia Mingroni-Netto
Journal:  J Hum Genet       Date:  2009-05-22       Impact factor: 3.172

10.  Identities and frequencies of mutations of the otoferlin gene (OTOF) causing DFNB9 deafness in Pakistan.

Authors:  B Y Choi; Z M Ahmed; S Riazuddin; M A Bhinder; M Shahzad; T Husnain; S Riazuddin; A J Griffith; T B Friedman
Journal:  Clin Genet       Date:  2009-03       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.